Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Bioresearch Wins $9.5M NIH Contract

NEW YORK (GenomeWeb News) – Genome customization firm Cellectis bioresearch today announced it has won a five-year, $9.5 million contract from the National Institutes of Health for work directed at induced pluripotent stem cells.

Under the terms of the contract, Cellectis bioresearch will provide services to NIH and certain other government agencies. The company will generate iPS cell lines of clinical grade and differentiate iPS cells toward specific tissue cell type of clinical grade.

The contract, which has a maximum order limit of $9,509,000, is the largest secured by Cellectis bioresearch, CEO Marc Le Bozec said.

Based in Paris, with an office in Cambridge, Mass., Cellectis bioresearch is a subsidiary of the Cellectis Group.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.